Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072057 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A4ALDH1A1PGRKDM4E | |
| SCHEMBL6909093 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4ALDH1A1PGRKDM4E | |
| SCHEMBL14663982 | 0.76 | SLC6A2 (0.50) | SLC6A2SLC6A4ALDH1A1PGRKDM4E | |
| SCHEMBL4621924 | 0.75 | ALDH1A1 (0.59) | SLC6A2SLC6A4ALDH1A1PGRKDM4E | |
| SCHEMBL14828688 | 0.75 | SLC6A2 (0.50) | SLC6A2SLC6A4ALDH1A1PGRMAPK1 | |
| SCHEMBL14664158 | 0.72 | SLC6A2 (0.47) | SLC6A2SLC6A4ALDH1A1KDM4EHPGD | |
| SCHEMBL9631422 | 0.71 | ALDH1A1 (0.50) | SLC6A2SLC6A4ALDH1A1PGRKDM4E | |
| SCHEMBL3142368 | 0.71 | SLC6A2 (0.72) | SLC6A2SLC6A4 | |
| SCHEMBL3137238 | 0.71 | SLC6A2 (0.72) | SLC6A2SLC6A4ALDH1A1PGR | |
| SCHEMBL3133100 | 0.71 | SLC6A2 (0.72) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598339-A1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | claimed |
| US-20050159452-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2005-07-21 | — | — | US | claimed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | claimed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1598338-B9 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | EP | disclosed |
| EP-1598339-B1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| EP-2050450-A1 | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2009-04-22 | — | — | EP | disclosed |
| EP-1598340-B1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZOXAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-03-04 | — | — | EP | disclosed |
| EP-1379246-B1 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2008-10-08 | — | — | EP | disclosed |
| EP-1930322-A1 | 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-06-11 | — | — | EP | disclosed |
| EP-1918279-A2 | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-05-07 | — | — | EP | disclosed |
| EP-1598340-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZOXAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598339-A1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598338-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| US-20050159452-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2005-07-21 | — | — | US | disclosed |
| US-6867222-B2 | Nociceptin analogs | EURO-CELTIQUE, S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156640-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | SLC6A2 532/4885SLC6A4 475/4885ALDH1A1 2797/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | SLC6A2 532/4885SLC6A4 475/4885ALDH1A1 2797/4885 |
| US-20030069249-A1 | Nociceptin analogs | OPRL1, NPY1R, OPRK1 | SLC6A2 660/4885SLC6A4 621/4885ALDH1A1 2130/4885 |
| US-20050159452-A1 | Nociceptin analogs | OPRL1, NPY1R, NPBWR1 | SLC6A2 532/4885SLC6A4 475/4885ALDH1A1 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.